They can also be engineered as targeting modules for chimeric antigen receptor (CAR)‐T cell therapies, drug conjugates, or photodynamic therapy agents.[34, 298, 299, 300] For instance, in photodynamic therapy, nanobody–photosensitizer conjugates have shown the ability to kill tumor cells that express GPCR selectively, and nanobody‐based CAR‐T cells have shown promise in the treatment of solid tumors [34, 299] By enhancing tumor selectivity and diminishing off‐target effects, nanobody–drug conjugates and nanobody‐functionalized nanoparticles further broaden the therapeutic toolkit [34, 298]. The gene discussed is FZD4; the disease is neoplasm.